Dr. Reddy’s outlines semaglutide relaunch in November 2026 and reiterates 6M-7M devices target

Despite revenue decline, the company has reconfirmed its resumption plan for 세마글루타이드 and device targets, resulting in a mixed neutral impact on the stock price.